IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients - IGC Pharma, INC.

Press

Releases

May 14, 2021

IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Related Posts

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research

February 26, 2026

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

February 24, 2026

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

February 23, 2026

CEO Update

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research

February 26, 2026

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

February 24, 2026